Abelcet Side Effects
Generic Name: amphotericin b lipid complex
Note: This document contains side effect information about amphotericin b lipid complex. Some of the dosage forms listed on this page may not apply to the brand name Abelcet.
For the Consumer
Applies to amphotericin b lipid complex: powder for solution, suspension
Along with its needed effects, amphotericin b lipid complex (the active ingredient contained in Abelcet) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking amphotericin b lipid complex:
- Difficulty in breathing
- sore throat and fever
- unusual bleeding or bruising
- unusual tiredness and weakness
- Increased or decreased urination
Some side effects of amphotericin b lipid complex may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- loss of appetite
- stomach pain
For Healthcare Professionals
Applies to amphotericin b lipid complex: intravenous suspension
General side effects during infusions have included fever (15%), chills (15%), and shivering. These symptoms usually begin 1 to 2 hours after the beginning of an amphotericin B lipid complex infusion, and are more common with the first few doses administered.
Severe infusion-related side effects have been associated with conventional amphotericin B administration, and may be lessened by treatment with corticosteroids, acetaminophen, antihistamines, and meperidine.[Ref]
Renal side effects have been reported less frequently with amphotericin B lipid complex than with conventional amphotericin B, and often included increased serum creatinine and BUN. Renal failure occurred in about 5% of treated patients. Decreased renal function, including oliguria, anuria, and renal tubular acidosis have also been reported.[Ref]
Metabolic side effects have occurred less frequently with amphotericin B lipid complex than with conventional amphotericin B. Hypokalemia and hypomagnesemia often accompany amphotericin-induced nephrotoxicity. Hypocalcemia has also been reported in treated patients.[Ref]
Gastrointestinal (GI) side effects, including nausea, vomiting, or diarrhea in 5% to 8% of patients, have been associated with amphotericin B lipid complex infusions. GI hemorrhage, abdominal pain, anorexia, dyspepsia, epigastric pain, cramping, malaise, and weight loss have occurred less frequently.[Ref]
Nervous system side effects have been reported rarely, except for headache, which occurred in about 4% of treated patients. Less frequently, convulsions, peripheral neuropathy visual impairment, including diplopia, hearing loss, tinnitus, and transient vertigo have been reported.[Ref]
Cardiovascular side effects including cardiac arrest and hypotension have been reported in 6% to 8% of treated patients. Hypertension, cardiac failure, cardiomyopathy, arrhythmias, and ventricular fibrillation have been uncommonly reported.[Ref]
Dermatologic side effects have included maculopapular rash, pruritus, and exfoliative dermatitis. Exanthema has been reported in a patient who was treated concomitantly with amphotericin B lipid complex and imipenem-cilastatin. The exact cause is unknown.[Ref]
Local side effects including thrombophlebitis and inflammation at the injection site have been reported.[Ref]
Musculoskeletal side effects including generalized bone, joint, or muscle pain have been reported.[Ref]
1. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN "Limited toxicity of prolonged therapy with high doses of amphotericin b lipid complex." Clin Infect Dis 21 (1995): 1154-8
2. Rapp RP, Gubbins PO, Evans ME "Amphotericin B lipid complex." Ann Pharmacother 31 (1997): 1174-86
3. Oravcova E, Mistrik M, Sakalova A, Drgona L, Kollar T, Helpianska L, Ilavska I, Sorkovska D, Spanik S, Kukuckova E, Krcmery V "Amphotericin b lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients." Chemotherapy 41 (1995): 473-6
4. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fanhavard P, Eng RHK, Patterson TF, "Amphotericin b lipid complex compared with amphotericin b in the treatment of cryptococcal meningitis in patients with AIDS." Clin Infect Dis 22 (1996): 315-21
5. "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.
6. Sundar S, Murray HW "Cure of antimony-unresponsive indian visceral leishmaniasis with amphotericin b lipid complex." J Infect Dis 173 (1996): 762-5
7. Lopez-Velez R, Videla S, Marquez M, et al. "Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients." J Antimicrob Chemother 53 (2004): 540-3
8. Sorkin P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P "Administration of amphotericin b in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients." Crit Care Med 24 (1996): 1311-5
9. Gales MA, Gales BJ "Acute renal failure with amphotericin B in lipid emulsion." Ann Pharmacother 30 (1996): 1036
10. Rowles DM, Fraser SL "Amphotericin B lipid complex (ABLC)-associated hypertension: Case report and review." Clin Infect Dis 29 (1999): 1564-5
Some side effects may not be reported. You may report them to the FDA.